Arthritis & Rheumatism, Volume 62,
November 2010 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Atlanta, Georgia November 6-11, 2010.


Oral N-acetylcysteine in the Treatment of Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Correa2,  Marcelo José Uchoa, Mariz3,  Henrique A., Andrade3,  Luis Eduardo Coelho, Kayser1,  Cristiane

Universidade Federal de São Palo, Brazil
Universidade Federal de São Paulo, São Paulo, Brazil
Universidade Federal de São Paulo, Brazil

Purpose:

Intravenous N-acetylcysteine has been suggested to be useful in the treatment of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). This study aimed to evaluate the safety and the efficacy of oral N-acetylcysteine on the digital skin microvascular blood flow in patients with RP secondary to SSc.

Methods:

This was a randomized, double-blind, placebo-controlled clinical trial with 42 patients with RP secondary to SSc. Patients were randomly assigned to receive oral N-acetylcysteine 600 mg three times daily or placebo three times daily for 4 weeks. Primary outcome was changes in digital skin microvascular blood flow before and after cold stimulus (CS) using laser Doppler imaging (LDI) at baseline and at week 4. Frequency of Raynaud's attacks, RP severity visual analog scale (VAS), RP pain VAS, and the number of digital ulcers were also evaluated at baseline and at week 4.

Results:

21 SSc patients (mean age 45.6±9.5 years) were randomly assigned to receive oral N-acetylcysteine and 21 patients (mean age 45.0±12.7 years), to receive placebo. Oral N-acetylcysteine was generally well tolerated, and at the end of 4 weeks nobody discontinue the treatment. There were no significant changes in digital skin blood flow measured by LDI before or after CS following 4 weeks of N-acetylcysteine or placebo. Both groups showed significant improvement of the frequency of Raynaud's attacks, RP severity VAS, and RP pain VAS after 4 weeks of treatment, with no difference between groups. There was no significant change in the number of digital ulcers in both groups after placebo or N-acetylcysteine treatment.

Conclusions:

Oral N-acetylcysteine did not demonstrate increase on the digital skin blood flow measured by laser Doppler imaging in this short-time study in patients with SSc. Oral N-acetylcysteine was not significantly better than placebo in improving severity of RP in patients with RP secondary to SSc.

To cite this abstract, please use the following information:
Correa, Marcelo José Uchoa, Mariz, Henrique A., Andrade, Luis Eduardo Coelho, Kayser, Cristiane; Oral N-acetylcysteine in the Treatment of Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. [abstract]. Arthritis Rheum 2010;62 Suppl 10 :579
DOI: 10.1002/art.28348

Abstract Supplement

Meeting Menu

2010 ACR/ARHP